论文部分内容阅读
目的:探讨肌细胞增强因子2C(myocyte enhancer factor 2C,MEF2C)表达情况与髓母细胞瘤患者预后的关系。方法:选取3家三级甲等医院2001-01-01-2007-12-31病理确诊的髓母细胞瘤患者56例,其中泰安市中心医院12例,齐鲁医院26例,山东省立医院18例;对照组脑组织取自泰安市中心医院2010-01-01-2010-12-31 12例非肿瘤脑外伤患者。免疫组织化学法检测56例髓母细胞瘤患者肿瘤组织和12例非肿瘤患者脑组织中MEF2C的表达;收集髓母细胞瘤患者临床资料,应用统计学方法对髓母细胞瘤患者进行生存分析。结果:髓母细胞瘤患者肿瘤组织MEF2C相对高表达率为53.6%(30/56),非肿瘤患者脑组织MEF2C相对高表达率为0(0/12),两组比较差异有统计学意义,χ2=11.50,P=0.001;肿瘤患者肿瘤组织MEF2C相对高表达组与相对低表达组间生存时间的差异有统计学意义,χ2=4.34,P=0.037。MEF2C相对高表达(P=0.023)、肿瘤转移(P=0.042)与患者3年生存率降低显著有关,而患者性别、年龄、肿瘤大小、肿瘤部位与患者3年生存率无关,P值均>0.05。结论:MEF2C在患者肿瘤组织中的高表达可降低患者3年生存率,是患者预后不良的危险因素之一。
Objective: To investigate the relationship between the expression of myocyte enhancer factor 2C (MEF2C) and the prognosis of patients with medulloblastoma. Methods: 56 patients with medulloblastoma diagnosed by pathology from 2001-01-01-2007-12-31 were selected, including 12 from Tai’an Central Hospital, 26 from Qilu Hospital, 18 from Shandong Provincial Hospital Cases; control group, brain tissue taken from Tai’an Central Hospital 2010-01-01-2010-12-31 12 cases of non-tumor brain injury patients. Immunohistochemistry was used to detect the expression of MEF2C in 56 cases of medulloblastoma and 12 cases of non-tumor. The clinical data of patients with medulloblastoma were collected, and the survival rate of medulloblastoma was analyzed statistically. Results: The high expression rate of MEF2C was 53.6% (30/56) in medulloblastoma patients and 0 (0/12) in non-tumor patients. The difference between the two groups was statistically significant, χ2 = 11.50, P = 0.001. There was significant difference in the survival time between cancer patients with relatively high MEF2C expression and relatively low expression group (χ2 = 4.34, P = 0.037). MEF2C expression was significantly higher (P = 0.023), tumor metastasis (P = 0.042) was significantly related to the reduction of 3-year survival rate of patients, but the gender, age, tumor size and tumor location were not related to the 3-year survival rate of patients. 0.05. Conclusion: The high expression of MEF2C in the tumor tissue of patients can reduce the 3-year survival rate of patients, which is one of the risk factors of poor prognosis.